China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease  
11/7/2007 11:17:01 AM

TOKYO--(BUSINESS WIRE)--GNI Ltd, a leading biopharmaceutical company in Japan and China, is pleased to announce that China’s Patent & Trademark Office has granted Shanghai Genomics, GNI’s wholly owned China subsidiary, regional patent rights relating to one of its lead drug candidates, F351 and its use (China Patent ZL 200380110691.0). This patent is a part of the Company’s global patent portfolio and provides protection for an important piece of its intellectual property in China.